Nymox Pharmaceutical Corp (NYMXF) Common Stock USD NPV
$0.0098
(3.27%)
- Add to watchlist
- This stock can be held in a
$0.0098
(3.27%)
Deal for just £11.95 per trade in a
Fund and Share Account
$0.0098
(3.27%)
Business summary
Nymox Pharmaceutical Corporation is a Canada-based biopharmaceutical company focused on developing its drug candidate, NX-1207, for treating benign prostatic hyperplasia (BPH) and low-grade localized prostate cancer. The Company’s activities and resources have been directed primarily at developing certain pharmaceutical technologies. Its products include Fexapotide Triflutate, NicAlert and TobacAlert. Fexapotide Triflutate is a protein injectable for benign prostatic hyperplasia (BPH) and for low grade localized prostate cancer. NicAlert is a simple test to determine smoking status. TobacAlert is a home test that provides an on-the-spot determination of a person’s level of exposure to tobacco products, including secondhand smoke. The Company started two pivotal double-blind placebo-controlled Phase III trials for NX-1207, NX02-0017 and NX02-0018, conducted at investigational sites across the United States with a total enrollment of approximately 1,000 patients.
Contact details
Important dates
General stock information
- Short code:
- NYMXF
- ISIN:
- BSP733981026
- Market cap:
- $25.18 million
- Shares in issue:
- 93.27 million
- Sector:
- Biotechnology
- Exchange:
- Off Exchange
- Country:
- Bahamas
- Currency:
- US dollar
- Indices:
- n/a
Key personnel
The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.